search
Back to results

Effects of Chocolate in Patients With Chronic Heart Failure

Primary Purpose

Heart Failure

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Nestlé Noir intense 40 grx2
Nestlé Placebo Chocolate 40 grx2
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring chocolate,, heart failure,, endothelial function,, platelet adhesion,, oxidative stress,, baroreceptor function,

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Heart failure ( NYHA ≥II, LVEF<50%, independent of aetiology)
  2. Nonsmokers
  3. Age: 30-80
  4. Written obtained informed consent

Exclusion Criteria:

  1. Decompensated Heart failure
  2. Instable Angina pectoris
  3. Smokers
  4. Ventricular tachyarrhythmias or AV-Block >I°
  5. Renal failure (>200 umol)
  6. Liver disease (ALT or AST >150 IU)
  7. Diabetes mellitus
  8. Obesity (BMI >30 kg/m2)
  9. Symptomatic hypotension, hypertension >160/100mmHg
  10. Known allergy to compounds of Nestlé noir intense
  11. History of gastric ulcer or bleeding, current diarrhea
  12. Venous thrombosis or pulmonary embolism, at present or recurrent history of Infectious disease, acutely or chronic
  13. Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
  14. Neoplasia (unless healed or remission >5 years)
  15. Participation in another study within the last month
  16. Concomitant vitamin supplements

Sites / Locations

  • Cardiovascular Center, Cardiology, University Hospital of Zurich

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.

Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.

Outcomes

Primary Outcome Measures

endothelial function

Secondary Outcome Measures

shear-stress dependent platelet function; Oxidative stress; baroreceptor function Systemic inflammatory response (assessed as change in high sensitivity CRP, 8-Isoprostanes, CD-40 ligand); Plasma epicatechins.

Full Information

First Posted
October 1, 2007
Last Updated
October 27, 2009
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT00538941
Brief Title
Effects of Chocolate in Patients With Chronic Heart Failure
Official Title
Effects of Swiss Dark Chocolate on Endothelial and Baroreceptor Function and Markers of Inflammation in Patients With Chronic Heart Failure
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
November 2005 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
October 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Zurich

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the present study is to investigate whether in patients with chronic heart failure endothelial dysfunction and baroreceptor function is altered by ingestion of a flavonoid-rich dark chocolate in comparison to placebo chocolate (Nestlé Placebo Chocolate) on top of standard medication. Moreover, we will evaluate the effect of chocolate on oxidative stress, platelet adhesion as well as systemic inflammatory response such as C-reactive protein and pro-inflammatory cytokines in patients with chronic heart failure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
chocolate,, heart failure,, endothelial function,, platelet adhesion,, oxidative stress,, baroreceptor function,

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
Intervention Type
Dietary Supplement
Intervention Name(s)
Nestlé Noir intense 40 grx2
Intervention Description
daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
Intervention Type
Dietary Supplement
Intervention Name(s)
Nestlé Placebo Chocolate 40 grx2
Intervention Description
Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
Primary Outcome Measure Information:
Title
endothelial function
Time Frame
acute (2 hours), chronic (2 and 4 weeks)
Secondary Outcome Measure Information:
Title
shear-stress dependent platelet function; Oxidative stress; baroreceptor function Systemic inflammatory response (assessed as change in high sensitivity CRP, 8-Isoprostanes, CD-40 ligand); Plasma epicatechins.
Time Frame
acute (2 hours), chronic (2 and 4 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Heart failure ( NYHA ≥II, LVEF<50%, independent of aetiology) Nonsmokers Age: 30-80 Written obtained informed consent Exclusion Criteria: Decompensated Heart failure Instable Angina pectoris Smokers Ventricular tachyarrhythmias or AV-Block >I° Renal failure (>200 umol) Liver disease (ALT or AST >150 IU) Diabetes mellitus Obesity (BMI >30 kg/m2) Symptomatic hypotension, hypertension >160/100mmHg Known allergy to compounds of Nestlé noir intense History of gastric ulcer or bleeding, current diarrhea Venous thrombosis or pulmonary embolism, at present or recurrent history of Infectious disease, acutely or chronic Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn) Neoplasia (unless healed or remission >5 years) Participation in another study within the last month Concomitant vitamin supplements
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georg Noll, MD
Organizational Affiliation
Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiovascular Center, Cardiology, University Hospital of Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
22173910
Citation
Flammer AJ, Sudano I, Wolfrum M, Thomas R, Enseleit F, Periat D, Kaiser P, Hirt A, Hermann M, Serafini M, Leveques A, Luscher TF, Ruschitzka F, Noll G, Corti R. Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J. 2012 Sep;33(17):2172-80. doi: 10.1093/eurheartj/ehr448. Epub 2011 Dec 15.
Results Reference
derived

Learn more about this trial

Effects of Chocolate in Patients With Chronic Heart Failure

We'll reach out to this number within 24 hrs